• Mycenax’s Actemra biosimilar edges closer to approval pharmaphorum
    January 02, 2019
    Mycenax’s biosimilar of Roche’s Actemra (tocilizumab), LusiNEX, has been shown to match its originator’s profile in a phase I PK trial, meaning it is on track to become the first approved biosimilar for the drug.
PharmaSources Customer Service